AR046611A1 - Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo - Google Patents
Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismoInfo
- Publication number
- AR046611A1 AR046611A1 ARP040103978A ARP040103978A AR046611A1 AR 046611 A1 AR046611 A1 AR 046611A1 AR P040103978 A ARP040103978 A AR P040103978A AR P040103978 A ARP040103978 A AR P040103978A AR 046611 A1 AR046611 A1 AR 046611A1
- Authority
- AR
- Argentina
- Prior art keywords
- present
- inhibitors
- thioxy
- haloalkylsulfinyl
- haloalkylsulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se provee composiciones farmacéuticas que contienen compuestos del presente, y métodos para utilizar los compuestos y composiciones del presente en el tratamiento de trastornos relacionados con el metabolismo, que incluyen dislipidemia, aterosclerosis, enfermedad cardiaca coronaria, resistencia a la insulina, diabetes tipo 2, Síndrome-X y similares. Además, el presente provee el uso de los compuestos del presente en combinación con otros agentes activos tales como los pertenecientes a la clase de inhibidores de alfa-glucosidasa, inhibidores de la aldosa reductasa, biguanidas, inhibidores de la HMG-CoA reductasa, inhibidores de la síntesis del escualeno, fibratos, intensificadores del catabolismo de las LDL, inhibidores de la enzima convertidora de angiotensina (ACE), intensificadores de la secreción de insulina y similares. Reivindicación 1: Un compuesto de fórmula (1), en la cual: X es NO o O; R1 se selecciona del grupo integrado por H, halógeno, hidroxi, tioxi, ciano, nitro, haloalquilo C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-5, haloalcoxi C1-4, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, haloalquiltio C1- 4, haloalquilsulfinilo C1-4 y haloalquilsulfonilo C1-4; R2 se selecciona del grupo integrado por H, halógeno, hidroxi, tioxi, ciano, nitro, haloalquilo C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-5, haloalcoxi C1-4, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, haloalquiltio C1-4, haloalquilsulfinilo C1-4 y haloalquilsulfonilo C1-4; o R2 está ausente; "línea y puntos" es un enlace simple cuando R2 está presente, o "línea y puntos" es un doble enlace cuando R2 está ausente; y el anillo A es un anillo carbocíclico de 5, 6 ó 7 miembros o un anillo heterocíclico de 5, 6 ó 7 miembros opcionalmente sustituido con 1 a 4 sustituyentes seleccionados del grupo integrado por halógeno, hidroxi, tioxi, ciano, nitro, haloalquilo C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-5, haloalcoxi C1-4, alquiltio C1- 4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, haloalquiltio C1-4, haloalquilsulfinilo C1-4 y haloalquilsulfonilo C1-4; o su sal, solvato o hidrato aceptable para uso farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51623803P | 2003-10-31 | 2003-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046611A1 true AR046611A1 (es) | 2005-12-14 |
Family
ID=34572875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103978A AR046611A1 (es) | 2003-10-31 | 2004-10-29 | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo |
Country Status (38)
Country | Link |
---|---|
US (2) | US8637555B2 (es) |
EP (2) | EP1599469B1 (es) |
JP (2) | JP4533898B2 (es) |
KR (1) | KR100850591B1 (es) |
CN (1) | CN1867562B (es) |
AR (1) | AR046611A1 (es) |
AT (1) | ATE328880T1 (es) |
AU (1) | AU2004287861B2 (es) |
BR (1) | BRPI0415631A (es) |
CA (1) | CA2539985C (es) |
CO (1) | CO5690551A2 (es) |
CR (1) | CR8270A (es) |
CY (1) | CY1105479T1 (es) |
DE (1) | DE602004001134T2 (es) |
DK (1) | DK1599469T3 (es) |
EA (1) | EA011484B1 (es) |
EC (1) | ECSP066529A (es) |
ES (1) | ES2267077T3 (es) |
GE (1) | GEP20094801B (es) |
HK (1) | HK1076468A1 (es) |
HR (1) | HRP20060286T3 (es) |
IL (1) | IL174042A0 (es) |
IS (1) | IS2372B (es) |
MA (1) | MA28171A1 (es) |
MX (1) | MXPA06004556A (es) |
MY (1) | MY140410A (es) |
NO (1) | NO20062509L (es) |
NZ (1) | NZ546285A (es) |
PE (1) | PE20050483A1 (es) |
PL (1) | PL1599469T3 (es) |
PT (1) | PT1599469E (es) |
RS (1) | RS20060290A (es) |
SI (1) | SI1599469T1 (es) |
TN (1) | TNSN06150A1 (es) |
TW (1) | TWI258478B (es) |
UA (1) | UA86783C2 (es) |
WO (1) | WO2005044816A1 (es) |
ZA (2) | ZA200603419B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
ES2331521T3 (es) | 2003-11-21 | 2010-01-07 | Arena Pharmaceuticals, Inc. | Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo. |
WO2006026273A2 (en) * | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
AU2005305086A1 (en) * | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
EP1877402A1 (en) * | 2005-04-28 | 2008-01-16 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
DE602006020447D1 (de) | 2005-06-28 | 2011-04-14 | Merck Sharp & Dohme | Niacin-rezeptoragonisten, zusammensetzungen mit de |
DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
JP6386478B2 (ja) | 2013-02-21 | 2018-09-05 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | メチル{4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1h−ピラゾロ[3,4−b]ピリジノ−3−イル]ピリミジノ−5−イル}メチルカルバメートの形態 |
US9975910B2 (en) | 2013-07-23 | 2018-05-22 | Eisai R&D Management Co., Ltd. | Hetero-fused cyclic compound |
CN103755637A (zh) * | 2013-12-26 | 2014-04-30 | 平湖优康药物研发有限公司 | 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺 |
CA3096145A1 (en) * | 2019-10-11 | 2021-04-11 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02178263A (ja) * | 1988-12-27 | 1990-07-11 | Kaken Pharmaceut Co Ltd | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 |
US5134155A (en) * | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
SK86699A3 (en) | 1996-12-23 | 2000-11-07 | Du Pont Pharm Co | Nitrogen containing heteroaromatics as factor xa inhibitors |
ATE451346T1 (de) | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
JP4292742B2 (ja) | 2000-03-09 | 2009-07-08 | 小野薬品工業株式会社 | インドール誘導体、その製造方法および用途 |
US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
CN1245974C (zh) | 2000-06-28 | 2006-03-22 | 特瓦制药工业有限公司 | 卡维地洛 |
JP4102185B2 (ja) | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
ES2272712T3 (es) | 2001-05-23 | 2007-05-01 | Merck Frosst Canada Ltd. | Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2. |
CN1245391C (zh) | 2001-06-01 | 2006-03-15 | 弗·哈夫曼-拉罗切有限公司 | 用作谷氨酸受体的嘧啶、三嗪和吡嗪衍生物 |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
DE60200346T2 (de) | 2001-06-27 | 2005-03-24 | Rs Tech Corp. | Neuer chiraler salen-katalysator und verfahren zur herstellung chiraler verbindungen aus racemischen epoxiden unter verwendung des neuen katalysators |
CA2459515A1 (en) | 2001-09-07 | 2003-03-20 | Kazuhiko Torisu | Indole derivatives |
DE10148617A1 (de) | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
RU2329256C2 (ru) | 2002-03-19 | 2008-07-20 | Оно Фармасьютикал Ко., Лтд. | Производное карбоновой кислоты, фармацевтическая композиция и средство для профилактики и/или лечения заболеваний, вызванных активацией dp-рецептора, применение производного карбоновой кислоты для производства такого средства, способ профилактики и/или лечения заболеваний, вызываемых активацией dp-рецепторов |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
US20060167270A1 (en) * | 2002-10-10 | 2006-07-27 | Arena Pharmaceuticals Inc. | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
EP1633351A1 (en) | 2003-06-13 | 2006-03-15 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
WO2005077950A2 (en) | 2004-02-14 | 2005-08-25 | Smithkline Beecham Corporation | Medicaments with hm74a receptor activity |
WO2006026273A2 (en) | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
AU2005305086A1 (en) | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
EP1877402A1 (en) | 2005-04-28 | 2008-01-16 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
-
2004
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/en active IP Right Grant
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 CA CA2539985A patent/CA2539985C/en not_active Expired - Fee Related
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
- 2004-10-29 EP EP04818324A patent/EP1599469B1/en not_active Not-in-force
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es active Active
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active IP Right Cessation
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de active Active
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 EP EP06005248A patent/EP1683794A1/en not_active Withdrawn
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
-
2005
- 2005-12-06 HK HK05111162A patent/HK1076468A1/xx not_active IP Right Cessation
-
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-08-24 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
-
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
EA200700099A1 (ru) | Производные пиридина | |
EA201170769A1 (ru) | Органические соединения | |
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
SV2008002969A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
UY29893A1 (es) | Derivados de pirazina | |
DE50302975D1 (de) | Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
AR068061A1 (es) | Derivados de bisamida biciclicos utiles como pesticidas | |
WO2007146124A3 (en) | Deuterated tadalafil derivatives | |
TN2009000160A1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides | |
AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
EA200100902A1 (ru) | Производные тетрагидропирана и их использование в качестве терапевтических агентов | |
ATE359791T1 (de) | Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer | |
EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
AR056087A1 (es) | Derivados de azetidina como antagonistas de receptores de neuroquina nk | |
EA200701843A1 (ru) | 2-оксо-1,2,4,5-тетрагидро-1,3-бензодиазепин-3-илпиперидины в качестве cgrp-антагонистов | |
ATE465151T1 (de) | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren | |
DE60327446D1 (de) | 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie | |
SE0403118D0 (sv) | New compounds 2 | |
ATE476420T1 (de) | Alkaloidverbindungen und ihre verwendung als antimalariamittel | |
WO2005051937A3 (en) | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |